Abattis Bioceuticals Corp (ATTBF)

[guay]

They sold their True Leaf shares - see 'Consolidated Financial Statements
For the three and nine months ended June 30, 2016 '

4. MARKETABLE SECURITIES
During the year ended September 30, 2015, the company acquired 980,000 shares of the Bi Optic Ventures Inc. at a cost of $49,000. The company disposed of 1,234,750 shares of Bi Optic Ventures Inc. and the remaining quantity and fair value is nil.
On February 9, 2015 the shares of the True Leaf was listed in Canadian Securities Exchange (“CSE”), therefore 1,333,333 shares of True Leaf were reclassified from investments to marketable securities (see also Note 10). During the period ended March 31, 2016, the Company disposed of 688,333 shares of the True leaf. As March 31, 2016, the Company held nil shares of True Leaf.
The Company recognized a loss of $9,855 (June 30, 2015 - $nil) regarding trading of the marketable securities, which was recognized in the consolidated statement of loss and comprehensive loss.

9. INVESTMENT
During the year ended September 30, 2014, the Company purchased 800,000 shares of True Leaf Medicine Corp. at a cost of $200,000. These securities were classified as available for sale since the shares of True Leaf Medicine Corp. did not have a quoted price in an active market.
On February 9, 2015, the common shares of True Leaf Medicine Corp. (“True Leaf”) were approved for listing on the CSE, therefore investment in True Leaf were reclassified as marketable securities (see also note 4). The Company received an additional 533,333 common shares as part of the listing.

Source: http://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo=00011477&issuerType=03&projectNo=02530882&docId=3980986